Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe genetic and skin disorders in Europe, the United States, and Singapore.
Flawless balance sheet with moderate growth potential.
Share Price & News
How has Clinuvel Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CLVL.F's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CLVL.F underperformed the US Biotechs industry which returned 26.8% over the past year.
Return vs Market: CLVL.F underperformed the US Market which returned 9.1% over the past year.
Price Volatility Vs. Market
How volatile is Clinuvel Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Clinuvel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CLVL.F ($15.71) is trading above our estimate of fair value ($2.54)
Significantly Below Fair Value: CLVL.F is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CLVL.F is poor value based on its PE Ratio (77.6x) compared to the Biotechs industry average (18.6x).
PE vs Market: CLVL.F is poor value based on its PE Ratio (77.6x) compared to the US market (15.9x).
Price to Earnings Growth Ratio
PEG Ratio: CLVL.F is poor value based on its PEG Ratio (9.7x)
Price to Book Ratio
PB vs Industry: CLVL.F is overvalued based on its PB Ratio (20.2x) compared to the US Biotechs industry average (3.7x).
How is Clinuvel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLVL.F's forecast earnings growth (8% per year) is above the savings rate (2.2%).
Earnings vs Market: CLVL.F's earnings (8% per year) are forecast to grow slower than the US market (21.7% per year).
High Growth Earnings: CLVL.F's earnings are forecast to grow, but not significantly.
Revenue vs Market: CLVL.F's revenue (23.4% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: CLVL.F's revenue (23.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CLVL.F's Return on Equity is forecast to be high in 3 years time
How has Clinuvel Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLVL.F has high quality earnings.
Growing Profit Margin: CLVL.F's current net profit margins (47.2%) are lower than last year (57.9%).
Past Earnings Growth Analysis
Earnings Trend: CLVL.F has become profitable over the past 5 years, growing earnings by 66.7% per year.
Accelerating Growth: CLVL.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CLVL.F had negative earnings growth (-4.7%) over the past year, making it difficult to compare to the Biotechs industry average (-4.5%).
Return on Equity
High ROE: CLVL.F's Return on Equity (26.1%) is considered high.
How is Clinuvel Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: CLVL.F's short term assets (A$60.8M) exceed its short term liabilities (A$4.0M).
Long Term Liabilities: CLVL.F's short term assets (A$60.8M) exceed its long term liabilities (A$98.8K).
Debt to Equity History and Analysis
Debt Level: CLVL.F is debt free.
Reducing Debt: CLVL.F has not had any debt for past 5 years.
Debt Coverage: CLVL.F has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CLVL.F has no debt, therefore coverage of interest payments is not a concern.
What is Clinuvel Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CLVL.F's dividend (0.1%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.69%).
High Dividend: CLVL.F's dividend (0.1%) is low compared to the top 25% of dividend payers in the US market (4.48%).
Stability and Growth of Payments
Stable Dividend: CLVL.F is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: CLVL.F is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: CLVL.F is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CLVL.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Philippe Wolgen (56yo)
Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group. ...
CEO Compensation Analysis
Compensation vs Market: Philippe's total compensation ($USD942.10K) is below average for companies of similar size in the US market ($USD3.20M).
Compensation vs Earnings: Philippe's compensation has been consistent with company performance over the past year.
|CEO, MD & Director||14.5yrs||AU$1.42m||7.09% A$56.5m|
|CFO & Company Secretary||14.33yrs||AU$336.50k||0.62% A$4.9m|
|Acting Chief Scientific Officer||7.67yrs||AU$296.35k||0.64% A$5.1m|
|Head of Investor Relations||no data||no data||no data|
|General Manager of Europe||no data||no data||no data|
Experienced Management: CLVL.F's management team is seasoned and experienced (14.3 years average tenure).
|CEO, MD & Director||14.5yrs||AU$1.42m||7.09% A$56.5m|
|Non-Executive Director||13.17yrs||AU$82.52k||0.36% A$2.9m|
|Non-Executive Director||0.67yr||no data||no data|
|Non Executive Director||0.50yr||no data||0.0034% A$27.3k|
|Non-Executive Chairman||0.50yr||AU$80.00k||3.53% A$28.1m|
|Non-Executive Director||2.33yrs||AU$65.00k||0.011% A$88.7k|
Experienced Board: CLVL.F's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Clinuvel Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
- Name: Clinuvel Pharmaceuticals Limited
- Ticker: CLVL.F
- Exchange: OTCPK
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$1.197b
- Listing Market Cap: AU$796.697m
- Shares outstanding: 49.41m
- Website: https://www.clinuvel.com
- Clinuvel Pharmaceuticals Limited
- 535 Bourke Street
- Level 11
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|UR9||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Feb 2001|
|CUV||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Feb 2001|
|CLVL.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Feb 2001|
|CUV||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Feb 2001|
|CLVL.Y||OTCPK (Pink Sheets LLC)||SPON ADR||US||USD||May 2004|
|UR9A||DB (Deutsche Boerse AG)||SPON ADR||DE||EUR||May 2004|
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe genetic and skin disorders in Europe, the United States, and Singapore. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria. The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with erythropoietic protoporphyria in the People's Republic of China. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/30 04:05|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.